Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 2,711,000 shares at $14.95 ($40.5M) on 2025-09-19, disclosed to the SEC on 2025-09-23.
Scheduled sale ($40.5M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.95 | 683,818 | $10.2M | 25.3% |
| 2 | $14.95 | 683,818 | $10.2M | 25.3% |
| 3 | $14.99 | 316,182 | $4.7M | 11.7% |
| 4 | $14.99 | 316,182 | $4.7M | 11.7% |
| 5 | $15.01 | 100,000 | $1.5M | 3.7% |
| 6 | $14.83 | 611,000 |
| $9.1M |
| 22.4% |
| Total | $14.93 avg | 2,711,000 | $40.5M | 100% |
| Filing → |
| ROIV | SELL | 2026-09-01 | $7.2M | — | Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |